Long-term protection of HPV test in women at risk of cervical cancer

To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology a...

Full description

Saved in:
Bibliographic Details
Published in:PloS one 2020-08, Vol.15 (8), p.e0237988-e0237988
Main Authors: Ibanez, Raquel, Roura, Esther, Monfil, Laura, Rodriguez, Luís Alejandro, Sarda, Montserrat, Crespo, Nayade, Pascual, Amparo, Marti, Clara, Fibla, Montserrat, Gutierrez, Cristina, Lloveras, Belen, Oliveras, Gloria, Torrent, Anna, Catala, Isabel, Bosch, Francesc Xavier, Bruni, Laia, de Sanjose, Silvia
Format: Article
Language:English
Subjects:
Biology and Life Sciences
Cancer screening
Cellular biology
Cervical cancer
Cervix
Clinical trials
Cytology
Diagnosis
Epidemiology
Evaluation
Health risks
Human papillomavirus
Immunologic tests
Infections
Intervals
Laboratories
Medical diagnosis
Medical records
Medical screening
Medicine and Health Sciences
Methods
Mortality
Oncology
Papillomavirus infections
Pathology
Patient outcomes
Public health
Reproductive health
Risk factors
Statistical tests
Women's health
Womens health
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:To evaluate the 9-year incidence of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and cumulative adherence to perform a next test in a cohort of women aged 40+ years with no cervical screening cytology within a window of 5 years (underscreened women), after baseline cervical cytology and HPV tests. In Catalonia, Spain, co-testing with cytology and HPV test has been recommended in the Public Health system since 2006 for underscreened women. In 2007, 1,594 women with underscreened criteria were identified and followed through medical records form Pathological Department. 9-year cumulative incidence of histologically confirmed CIN2+ and cumulative adherence to perform a next test were estimated using Kaplan-Meier statistics. Follow-up was available for 1,009 women (63.3%) resulting in 23 women with. CIN2+ (2.3%). Of them, 4 women (17%) had both tests negative at baseline (3CIN2 and 1CIN3) with cumulative incidence of CIN2+ of 0.4% (95% CI: 0.1-1.4) at 5-years and 1.3% (95% CI: 0.4-3.7) at 9-years. During the first year, the prevalence among women with both tests positive was 27.0% (95% CI: 13.0-50.6) for CIN2+. Lost to follow-up was higher among women with both tests negative compared to those with both positive tests (38.7% vs 4.2%, p-value
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0237988